PepTivator® CEF MHC Class I Plus

PepTivator® CEF MHC Class 1 Plus consists of 32 MHC-1– specific peptides of 8–12 aa in length. These sequences were derived from cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and influenza virus and have been shown to elicit interferon-gamma release from CD8+ T cells in most of all individuals1,2.

In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

... read more

Related products for PepTivator® CEF MHC Class I Plus

Specifications for PepTivator® CEF MHC Class I Plus
Overview

PepTivator® CEF MHC Class 1 Plus consists of 32 MHC-1– specific peptides of 8–12 aa in length. These sequences were derived from cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and influenza virus and have been shown to elicit interferon-gamma release from CD8+ T cells in most of all individuals1,2.

In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Detailed product information
Downstream applications
  • PepTivator CEF MHC Class 1 Plus is recommended as a peptide-specific positve control for the detection of CD8+ T cells in human PBMC. This peptide set is used by the NIH. For more information refer to the NIH AIDS Research and Reference Reagent Program.
Product data and images for PepTivator® CEF MHC Class I Plus
Figure 1

Sequences and HLA restrictions of peptides of the PepTivator CEF MHC Class I Plus peptide pool.HLA-allele data according to www.iedb.org.

Citations for PepTivator® CEF MHC Class I Plus
Publications
  1. Currier, J. R. et al. (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260 (1-2): 157-172
  2. Mwau, M. et al. (2002) Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18 (9): 611-618

You have previously chosen International as your location.
What do you want to do?